Calcium–Magnesium Absorption Competition: Clinical Implications for Protocol Design

Calcium and magnesium share intestinal transport machinery — primarily TRPM7 and members of the SLC family — creating competitive dynamics that have direct consequences for mineral repletion outcomes. In clinical practice, the co-administration of calcium and magnesium supplements is common, but the pharmacokinetic case for separating them is strong and underappreciated.

Mechanism

Both Ca²⁺ and Mg²⁺ are absorbed via shared divalent cation transporters in the small intestine. Transcellular absorption predominates at lower luminal concentrations and is saturable. At therapeutic supplementation doses — particularly calcium doses above 200–250mg — transporter saturation begins to limit magnesium uptake due to competitive inhibition.

The clinical relevance is amplified by the fact that magnesium deficiency is pervasive in clinical populations. Subclinical deficiency is common even in patients eating adequate diets, due to soil depletion, medication interference (PPIs, diuretics, fluoroquinolones), and high physiological demand. Practitioners recommending both minerals simultaneously may be inadvertently undermining magnesium repletion — particularly in cases where calcium dosing is high.

Evidence Summary

Randomized absorption studies using isotopically labeled minerals demonstrate measurable reductions in Mg²⁺ fractional absorption when co-administered with calcium at doses ≥500mg. The interference is dose-dependent and more pronounced at higher calcium-to-magnesium molar ratios.

Epidemiological data on dietary Ca:Mg ratios are consistent with these mechanistic findings. Populations with ratios above 2.6:1 show higher rates of conditions associated with functional magnesium insufficiency — including cardiovascular risk markers, insulin resistance, and sleep architecture disruption — independent of absolute magnesium intake.

Protocol Design Implications

Timing separation: A minimum two-hour window between calcium and magnesium supplementation is supported by the absorption data and represents the lowest-friction clinical intervention. Calcium with meals (particularly lunch, given digestive acid support) and magnesium in the evening is a practical default.

Form selection: Magnesium glycinate and magnesium malate have favorable absorption profiles and distinct clinical applications (sleep vs. energy/fatigue respectively). Magnesium oxide should generally be avoided for repletion purposes due to low bioavailability (~4%).

Ca:Mg ratio audit: Review the total calcium and magnesium load across all products in the patient’s stack — not just dedicated supplements. Calcium is present in protein powders, greens blends, fortified foods, and antacids. The effective ratio in many stacks is significantly higher than practitioners realize.

Monitoring: Serum magnesium is an insensitive marker for tissue deficiency (only ~1% of total body magnesium is extracellular). RBC magnesium, where accessible through functional lab panels, provides a more clinically meaningful picture of repletion status.

Clinical Scenarios Where This Matters Most

Patients presenting with persistent sleep fragmentation, muscle cramping, or anxiety who are already on magnesium supplementation should prompt a protocol audit before dose escalation. Concurrent calcium use — particularly at doses above 500mg — is a frequently missed variable.

Similarly, postmenopausal patients on calcium for bone density who are simultaneously presenting with fatigue or neuromuscular symptoms may be experiencing functional magnesium insufficiency driven by competitive absorption rather than inadequate intake.

The Stack Intelligence Gap

This interaction is knowable from the literature. The clinical problem is that no current tool gives practitioners systematic visibility into it across a full patient stack — accounting for all sources, not just dedicated mineral supplements. That’s the problem StaqWell’s interaction graph is being built to address.

Apply for the Founding Practitioner Cohort